Liver function may predict dangerous side effect in common breast cancer drug

NCT ID NCT05912933

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study looks at whether breast cancer patients with mild, moderate, or severe liver problems face a higher risk of a serious side effect—grade 4 neutropenia (a dangerous drop in infection-fighting white blood cells)—when taking the drug palbociclib. Researchers analyzed medical records from over 1,300 patients across 23 hospitals in Japan. The goal is to understand how liver impairment influences this side effect, which could help doctors tailor treatment and monitoring for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib
What this could lead to: If it works, this could help doctors better predict and manage severe neutropenia risk in breast cancer patients with liver problems who take palbociclib.
What could go wrong: This is an observational study using existing data, not a controlled trial. Results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Pfizer New York

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.